NEW YORK, Oct. 21 (GenomeWeb News) - Bruker BioSciences, which formed on July 1 through the merger of Bruker Daltonics and Bruker AXS, said yesterday that it is embarking upon a cost-cutting consolidation strategy that goes "beyond the original merger plan."
The restructuring, which has already been partially implemented and is expected to be finalized in the second quarter of 2004, includes the consolidation of the Bruker AXS x-ray systems production in Madison, Wis. The company will also outsource or transfer to its other production centers the manufacturing of certain technologies previously manufactured by Bruker-Nonius, a subsidiary of Bruker AXS located in Delft, The Netherlands. This business will now focus on applications for life science x-ray crystallography and structural proteomics, as well as on marketing and customer support, the company said. In addition, the Bruker Daltonics business will phase out manufacturing of substance detection products at its Faellanden, Switzerland, site by the end of the second quarter of 2004.
Bruker BioSciences said the consolidation plan should improve its operating performance by $2.5 million to $3.0 million annually pre-tax, beginning in the third quarter of 2004.